Posts by: Iqra Mumal

News

A small molecule known as mir-494-3p might play a protective role in the survival of motor nerve cells, a discovery that could lead to the development of new therapies ... Read more

October 1, 2018

FUS Mutations Likely Cause ALS by Preventing Repair of Oxidative Damage in DNA

News

FUS — a protein mutated in some amyotrophic lateral sclerosis patients — plays a key role in the mechanism that repairs oxidative damage in DNA molecules in motor neurons, ... Read more

September 25, 2018

Noxopharm and Nyrada Discover Potent Inhibitor of Key Protein Involved in ALS, Other Conditions

News

The pharmaceutical development company Noxopharm and its majority-owned subsidiary, U.S. biotechnology firm Nyrada, have discovered a potent inhibitor of the protein IRAK4, a “master switch” critical to the development of ... Read more

September 19, 2018September 19, 2018

New Method Described in Thesis Can Help Characterize and Target Misfolded Protein in ALS

News

A newly developed method can help characterize the types of misfolded proteins present in patients with amyotrophic lateral sclerosis (ALS), according to findings in a thesis. The recently published ... Read more

September 11, 2018September 11, 2018

Nerve Cell Death Signaling May Hold Key to Treating ALS, Other Diseases, Study Finds

News

A new process by which pro-death signaling is sent to nerve cells may hold the key for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), which is characterized ... Read more

September 5, 2018September 5, 2018

Systems Using Brain Signals to Communicate Can Help Advanced ALS Patients, But Improvements Needed

News

The Wadsworth Brain-Computer Interface (BCI) can help amyotrophic lateral sclerosis (ALS) patients who are severely disabled to communicate while in the home, a study reports, especially those in fairly ... Read more

August 23, 2018August 23, 2018

Tikomed Gets OK to Begin Phase 2 Trial in UK Testing Investigational ALS Therapy ILB

News

The Medicines and Healthcare products Regulatory Agency in the United Kingdom has granted permission to Tikomed to begin a Phase 2 clinical trial to evaluate the safety and effectiveness ... Read more

August 22, 2018August 22, 2018

Extracts from Medicinal Plant Improved Motor Function, Delayed Disease Worsening in ALS Mice, Study Finds

News

Treatment with extracts from the Withania somnifera plant improved motor performance and delayed disease progression in mice with amyotrophic lateral sclerosis (ALS), according to researchers. The study, “Protective effects of Withania somnifera extract in SOD1G93A mouse model ... Read more

August 16, 2018August 16, 2018

Arrows and Colors Test Measures Cognition in Severe ALS Patients

News

A newly developed test, known as the arrows and colors cognitive test, can be used to measure cognition in amyotrophic lateral sclerosis (ALS) patients who have severe motor and ... Read more

August 14, 2018August 30, 2018

Orphazyme Doses First ALS Patient in Phase 3 Trial of Arimoclomol

News

The first patient has been dosed in a Phase 3 clinical trial (NCT03491462) evaluating the effectiveness of Orphazyme’s investigational therapy arimoclomol in the treatment of amyotrophic lateral sclerosis (ALS). One of ... Read more

Posts by: Iqra Mumal

Iqra Mumal

Protective Role of microRNA May Hold Therapeutic Potential for ALS, Study Shows

FUS Mutations Likely Cause ALS by Preventing Repair of Oxidative Damage in DNA

Noxopharm and Nyrada Discover Potent Inhibitor of Key Protein Involved in ALS, Other Conditions

New Method Described in Thesis Can Help Characterize and Target Misfolded Protein in ALS

Nerve Cell Death Signaling May Hold Key to Treating ALS, Other Diseases, Study Finds

Systems Using Brain Signals to Communicate Can Help Advanced ALS Patients, But Improvements Needed

Tikomed Gets OK to Begin Phase 2 Trial in UK Testing Investigational ALS Therapy ILB

Extracts from Medicinal Plant Improved Motor Function, Delayed Disease Worsening in ALS Mice, Study Finds

Arrows and Colors Test Measures Cognition in Severe ALS Patients

Orphazyme Doses First ALS Patient in Phase 3 Trial of Arimoclomol

Pin It on Pinterest